Table 1 Baseline characteristics
Placebo (n = 7) | Dapagliflozin 10 mg (n = 7) | P value | |
|---|---|---|---|
Male sex, N (%) | 4 (57.1) | 7 (100) | |
Age, yeras | 67 ± 2.4 | 65.1 ± 2.7 | P = 0.6 |
Diabetes duration, years | 8 ± 0.7 | 5.8 ± 0.9 | P = 0.1 |
HbA1c, % | 8 ± 0.2 | 7.8 ± 0.2 | P = 0.5 |
Fasting glycemia (mg/dl) | 121 ± 10.5 | 141.7 ± 11.3 | P = 0.1 |
C-peptide (ng/ml) | 1.2 ± 0.3 | 1.9 ± 0.2 | P = 0.1 |
BMI, kg/ml2 | 29.1 ± 1.2 | 27.8 ± 1.1 | P = 0.8 |
Body weight, kg | 79.2 ± 4.3 | 83 ± 2.5 | P = 0.4 |
Heart rate, bpm | 70.4 ± 4.3 | 60.7 ± 4.4 | P = 0.2 |
Systolic BP, mmHg | 135.7 ± 5.6 | 145 ± 5.5 | P = 0.35 |
Diastolic BP, mmHg | 70 ± 3.9 | 69.2 ± 2.7 | P = 0.9 |
CAD (previous PCI/no PCI) | 4/3 | 2/5 | P = 0.2 |
eGFR (ml/min) | 93 ± 2.2 | 86.8 ± 6.7 | P = 0.45 |
Medications | |||
Metformin | 7 (100) | 6 (85.7) | |
DPP-4i | 3 (42.2) | 2 (28.5) | |
GLP-1 RA | 2 (28.5) | 1 (14.2) | |
Basal insulin | 1 (14.2) | 2 (28.5) | |
Sulfonylurea | 1 (14.2) | 1 (14.2) | |